Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines

Xin-Bo Xue1, Chao-Wen Xiao, Hui Zhang

  • 1Department of Biliary and Pancreatic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.

Abstract

Insights

Oncolytic adenovirus SG600-IL24 selectively inhibits hepatocellular carcinoma (HCC) cell growth and induces apoptosis. This enhanced antitumor activity in HCC cells shows promise for liver cancer treatment.

Area of Science:

  • Oncolytic virotherapy
  • Hepatocellular carcinoma research
  • Gene therapy

Background:

  • Hepatocellular carcinoma (HCC) remains a significant global health challenge.
  • Targeted therapies are crucial for improving HCC treatment outcomes.
  • Oncolytic viruses offer a promising strategy for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of oncolytic adenovirus SG600-IL24 and Ad.IL-24 against HCC cell lines.
  • To assess the impact of these adenoviruses on normal liver cells.
  • To investigate the mechanism of action, including gene expression and cell cycle effects.

Main Methods:

  • Infection of HCC cell lines (HepG2, Hep3B, MHCC97L) and a normal liver cell line (L02) with SG600-IL24 and Ad.IL-24.
  • Detection of MDA-7/IL-24 expression using RT-PCR, ELISA, and Western blotting.
  • Assessment of apoptosis via cytometric assay and cell proliferation/cell cycle via MTT and flow cytometry.

Main Results:

  • SG600-IL24 demonstrated high expression of exogenous MDA-7/IL-24.
  • Significant suppression of HCC cell growth (72-85% inhibition) and induction of apoptosis (43-78% rate) by SG600-IL24.
  • Cell cycle arrest at G2/M phase in HCC cells (35-47% rate) without affecting normal liver cells.
  • These effects were observed in a p53-independent manner.

Conclusions:

  • SG600-IL24 selectively inhibits proliferation and induces apoptosis in HCC cell lines in vitro.
  • The normal liver cell line L02 was not affected by SG600-IL24.
  • SG600-IL24 exhibits enhanced antitumor activity compared to Ad.IL-24 in HCC cell lines.